Telemetry Investments' Q3 vs. Q4 13F Holdings: Winners, Losers, and Trends
Ava Hoppe | 4 May, 2023
As an investor, staying on top of changes in fund holdings can provide valuable insights into market trends and emerging opportunities. Telemetry Investments' latest 13F filings reveal interesting shifts in the firm's portfolio. In this article, we'll delve into the winners, losers, and overall trends in Telemetry's Q3 vs. Q4 2022 holdings.
First up, the winners. Among Telemetry's highest gainers were Moneygram Intl Inc (MGI), a money transfer company that saw a whopping 47.9% increase in shares. The pharmaceutical company, Amryt Pharma PLC (AMYT), also saw a healthy 11.8% increase. Bioplus Acquisition Corp (BIOS) and Valuence Merger Corp I (VMCAU) were other notable winners, with 2.7% and 2.3% increases, respectively.
On the flip side, there were a handful of losers among Telemetry's Q3 vs. Q4 holdings. Eiger BioPharmaceuticals (EIGR) saw a sharp drop of 69.7% in shares, while Mind Medicine MindMed Inc (MNMD) decreased by 42.8%. Nabors Industries Ltd (NBR) and Tegna Inc (TGNA) were also among the losers, experiencing a 12.7% and 19.9% decrease in shares, respectively.
Looking at overall trends, one of the most interesting takeaways from Telemetry's filings was the significant increase in the shares of Silver Spike Acquisiton (SPKB). The special purpose acquisition company saw a small 1.7% increase in shares, but the value of those shares increased from $2.7 million to $2.8 million. This suggests that Telemetry may be placing more emphasis on SPAC investments in the future.
Another trend we noticed was the growing interest in healthcare and pharmaceuticals among Telemetry's holdings. Atyr Pharma Inc (LIFE), Paratek Pharmaceuticals Inc (PRTK), and Esperion Therapeutics Inc NE (ESPR) all saw substantial increases in shares. This could be a response to the ongoing COVID-19 pandemic and a desire to invest in companies that are leading the charge in medical advancements.
Overall, Telemetry's Q3 vs. Q4 holdings provide a snapshot of the firm's current investment strategies and interests. While there were some notable losers, there were also several winners and emerging trends that investors should keep an eye on moving forward.
Other Posts
- Trading Strategies: A Review of Marathon Trading Investment Management LLC's Q3 vs. Q4 2022 Holdings
- The Future of Investor Relations: Providence Equity Welcomes Industry Veteran Katie Lyndon
- Greenwoods Asset Management Ltd Q3 2020 vs Q4 2020: 13F Holdings Comparison
- Armor Investment Advisors, LLC Q1 2023 vs. Q2 2023 13F Holdings Comparison
- Beech Hill Advisors, Inc. Q3 2023 vs. Q4 2023 13F Holdings Comparison
- Expanding Piñon Midstream's Dark Horse Treating Facility for Sustainable Energy Production
- How Eqis Capital Management's Shift in Holdings is Impacting the Market
- **Title: Navidea Biopharmaceuticals Files Form 15, Streamlining Reporting Obligations for Strategic Focus**
- The Berkshire Partners LLC Q3 2022 vs. Q4 2022 13F Holdings Comparison: A Detailed Look
- Exploring the Shifts in Investment Trends: Trilogy Capital Inc.'s Latest Portfolio Moves